PDMR dealing and Total Voting Rights

Allergy Therapeutics PLC

13 December 2023

 

Allergy Therapeutics plc

("Allergy Therapeutics", or the "Company")

Exercise of Options, PDMR dealing and Total Voting Rights

13 December 2023 Allergy Therapeutics plc (AIM: AGY), the integrated commercial biotechnology company specialising in allergy vaccines, announces that, further to his intention outlined in the mandatory offer document published on 19 October 2023, Manuel Llobet, Chief Executive Officer of the Company, exercised options over 1,676,200 ordinary shares ("Ordinary Shares") in the Company on 16 November 2023, which were granted at nominal value pursuant to the Company's 2013 Long Term Incentive Plan. The Ordinary Shares were issued and subsequently admitted to trading on 1 December 2023 pursuant to the Company's block admission facility.

Following the option exercise, Manuel Llobet holds 5,001,200 Ordinary Shares in the Company, representing approximately 0.10% of the issued share capital of the Company.

Pursuant to the Company's block admission facility, the Company also issued 888,967 Ordinary Shares in satisfaction of the exercise of share options by certain other current and former employees. These Ordinary Shares were also admitted to trading on 1 December 2023. The share options were exercised prior to or on 16 November 2023 as a result of the recent equity financing that constituted a change of control for the purposes of the Company's Long Term Share Incentive Plan. Any options not exercised by 16 November 2023 have lapsed.

The new Ordinary Shares rank pari passu with the Company's existing shares.

Total Voting Rights

In accordance with DTR 5.6.1 of the Financial Conduct Authority's Disclosure Guidance and Transparency Rules, as at 13 December 2023, the Company has 4,766,439,938 Ordinary Shares in issue. There are no shares held in treasury. The total number of voting rights in the Company is therefore 4,766,439,938.

The above figure of 4,766,439,938 may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

- ENDS -

For further information, please contact:

Allergy Therapeutics

Manuel Llobet, Chief Executive Officer

Shaun Furlong, Chief Financial Officer

[phone]

Panmure Gordon

Emma Earl, Mark Rogers, Freddy Crossley, Corporate Finance

Rupert Dearden, Corporate Broking

[phone]

ICR Consilium

Mary-Jane Elliott / David Daley / Davide Salvi

[phone]

[e-mail]

Notes for editors:

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company, headquartered in the UK, focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development includes vaccines for grass, tree, house dust mite and peanut. For more information, please see www.allergytherapeutics.com.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Manuel Llobet
2	Reason for the notification
a)	Position/status	Person Discharging Managerial Responsibilities (PDMR) - Chief Executive Officer
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Allergy Therapeutics plc
b)	LEI	213800PQ7AHK7KGVOE23
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Options over ordinary shares of £0.001 each
	Identification code	ISIN: GB00B02LCQ05
b)	Nature of the transaction	Exercise of options
c)	Price(s) and volume(s)	Volume: 1,676,200 Exercise price: £0.001
d)	Aggregated information	N/A
e)	Date of the transaction	16 November 2023
f)	Place of the transaction	Outside of a trading venue

 

END